SGLT2 inhibitors are linked to side effects such as genital infections, dehydration, and dizziness, which may increase the risk for falls in older adults. GLP-1 drugs often cause nausea and weight ...

Investigators studied response to standard chronic kidney disease (CKD) therapies among real-world patients with monogenic forms of glomerular disease.

Please provide your email address to receive an email when new articles are posted on . Treatment with sodium-glucose cotransporter-2 inhibitors for type 2 diabetes may reduce the risk for rheumatoid ...

Use of SGLT-2 inhibitor therapy at hospital admission is associated with a 32% reduced risk for acute kidney injury in ...

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. The primary outcome was ...

BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among patients with pulmonary arterial hypertension (PAH), according to an ...

SGLT2 inhibitors were linked to reduced heart transplant rejection in diabetes, though survival benefits remain unclear. Read ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 and GLP-1 agents were linked to lower risk of kidney-related outcomes for adults with type 2 diabetes and ...

Patients with SGLT2 inhibitor-associated diabetic ketoacidosis (DKA) received significantly lower doses of insulin in the first 24 hours of treatment compared with patients with type 1 diabetes DKA, ...

SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, ...